Treatment of severe allergic conjunctivitis with antolimab indicated improvement of ocular signs and symptoms and reduction of severity of comorbid atopic diseases in a phase 1b open-label study

Treatment of severe allergic conjunctivitis with antolimab indicated improvement of ocular signs and symptoms and reduction of severity of comorbid atopic diseases in a phase 1b open-label study